Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2013

01-06-2013 | Epidemiology

Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ

Authors: Laura C. Collins, Ninah Achacoso, Reina Haque, Larissa Nekhlyudov, Suzanne W. Fletcher, Charles P. Quesenberry Jr., Stuart J. Schnitt, Laurel A. Habel

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

We aimed to identify clinicopathologic factors associated with local recurrence (LR) in a large population of DCIS patients treated with breast-conserving therapy between 1990–2001 in three health plans. Regression methods were used to estimate relative risks (RR) of LR. Among 2,995 patients, 325 had a LR [10.9 %; median follow-up 4.8 years (range 0.5–15.7)]. After adjusting for health plan and treatment, risk of LR was increased among women <45 years (RR = 2.1, 95 % CI 1.5–2.8), African-Americans (RR = 1.6; 95 % CI 1.1–2.1) and those with DCIS detected because of signs/symptoms (RR = 1.6; 95 % CI 1.2–2.0). After also adjusting for age and diagnosis year, pathologic features associated with increased LR were larger lesion size (RR = 2.9 for ≥20 low power fields of DCIS; 95 % CI 1.6–5.6) and involved (RR = 2.9; 95 % CI 1.6–5.2), or close margins (RR = 2.4; 95 % CI 1.6–3.8). Presentation with symptoms/signs was associated with increased risk of invasive recurrence; while African-American race, larger tumor size, and involved/close tumor margins were more strongly associated with increased risk of DCIS recurrence. Our findings suggest some risk factors differ for non-invasive and invasive LRs and that most factors are only moderately associated with increased LR risk. Future research efforts should focus on non-clinicopathologic factors to identify more powerful risk factors for LR.
Literature
1.
go back to reference Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546–1554PubMedCrossRef Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546–1554PubMedCrossRef
2.
go back to reference Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129(1):165–173PubMedCrossRef Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129(1):165–173PubMedCrossRef
3.
go back to reference Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151PubMedCrossRef Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151PubMedCrossRef
4.
go back to reference Wong JS, Kaelin CM, Troyan SL et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036PubMedCrossRef Wong JS, Kaelin CM, Troyan SL et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036PubMedCrossRef
5.
go back to reference Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) 8-year update of Protocol B-17: intraductal carcinoma. Cancer 86(3):429–438PubMedCrossRef Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) 8-year update of Protocol B-17: intraductal carcinoma. Cancer 86(3):429–438PubMedCrossRef
6.
go back to reference Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102PubMedCrossRef Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102PubMedCrossRef
7.
go back to reference Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: 10-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387PubMedCrossRef Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: 10-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387PubMedCrossRef
8.
go back to reference Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCrossRef Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCrossRef
9.
go back to reference Schnitt SJ (2010) Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010(41):158–161PubMedCrossRef Schnitt SJ (2010) Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010(41):158–161PubMedCrossRef
10.
go back to reference Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000PubMedCrossRef Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000PubMedCrossRef
11.
go back to reference Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef
12.
go back to reference Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ (2008) Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 15(1):235–243PubMedCrossRef Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ (2008) Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 15(1):235–243PubMedCrossRef
13.
go back to reference Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95(22):1692–1702PubMedCrossRef Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95(22):1692–1702PubMedCrossRef
14.
go back to reference Solin LJ, Fourquet A, Vicini FA et al (2005) Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6):1137–1146PubMedCrossRef Solin LJ, Fourquet A, Vicini FA et al (2005) Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6):1137–1146PubMedCrossRef
15.
go back to reference Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed
16.
go back to reference Solin LJ, McCormick B, Recht A et al (1996) Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am 2(3):158PubMed Solin LJ, McCormick B, Recht A et al (1996) Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am 2(3):158PubMed
17.
go back to reference Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28(4):400–418PubMedCrossRef Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28(4):400–418PubMedCrossRef
18.
go back to reference Goldstein NS, Kestin L, Vicini F (2000) Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol 24(8):1058–1067PubMedCrossRef Goldstein NS, Kestin L, Vicini F (2000) Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol 24(8):1058–1067PubMedCrossRef
19.
go back to reference Vicini FA, Kestin LL, Goldstein NS et al (2000) Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy. J Clin Oncol 18(2):296–306PubMed Vicini FA, Kestin LL, Goldstein NS et al (2000) Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy. J Clin Oncol 18(2):296–306PubMed
20.
go back to reference Van Zee KJ, Liberman L, Samli B et al (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer 86(9):1757–1767PubMedCrossRef Van Zee KJ, Liberman L, Samli B et al (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer 86(9):1757–1767PubMedCrossRef
21.
go back to reference Habel LA, Achacoso NS, Haque R et al (2009) Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 11(6):R85PubMedCrossRef Habel LA, Achacoso NS, Haque R et al (2009) Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 11(6):R85PubMedCrossRef
22.
go back to reference Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott-Raven, Philadelphia Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott-Raven, Philadelphia
23.
go back to reference Latouche A, Porcher R, Chevret S (2004) Sample size formula for proportional hazards modelling of competing risks. Stat Med 23(21):3263–3274PubMedCrossRef Latouche A, Porcher R, Chevret S (2004) Sample size formula for proportional hazards modelling of competing risks. Stat Med 23(21):3263–3274PubMedCrossRef
24.
go back to reference Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef
25.
go back to reference Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, Hoboken Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, Hoboken
26.
go back to reference Collins LC, Achacoso N, Nekhlyudov L et al (2009) Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 33(12):1802–1808PubMedCrossRef Collins LC, Achacoso N, Nekhlyudov L et al (2009) Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 33(12):1802–1808PubMedCrossRef
27.
go back to reference Turaka A, Freedman GM, Li T et al (2009) Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol 100(1):25–31PubMedCrossRef Turaka A, Freedman GM, Li T et al (2009) Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol 100(1):25–31PubMedCrossRef
28.
go back to reference Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393–1403PubMedCrossRef Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393–1403PubMedCrossRef
29.
go back to reference Haque R, Achacoso NS, Fletcher SW et al (2010) Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 16(5):351–360PubMed Haque R, Achacoso NS, Fletcher SW et al (2010) Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 16(5):351–360PubMed
30.
go back to reference Nassar H, Sharafaldeen B, Visvanathan K, Visscher D (2009) Ductal carcinoma in situ in African-American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer 115(14):3181–3188PubMedCrossRef Nassar H, Sharafaldeen B, Visvanathan K, Visscher D (2009) Ductal carcinoma in situ in African-American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer 115(14):3181–3188PubMedCrossRef
31.
go back to reference Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCrossRef Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCrossRef
32.
go back to reference Rudloff U, Brogi E, Brockway JP et al (2009) Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 115(6):1203–1214PubMedCrossRef Rudloff U, Brogi E, Brockway JP et al (2009) Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 115(6):1203–1214PubMedCrossRef
33.
go back to reference Adepoju LJ, Symmans WF, Babiera GV et al (2006) Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42–50PubMedCrossRef Adepoju LJ, Symmans WF, Babiera GV et al (2006) Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42–50PubMedCrossRef
34.
go back to reference Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010(41):162–177PubMedCrossRef Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010(41):162–177PubMedCrossRef
35.
go back to reference Solin LJ, Gray R, Baeher FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res 71(24 (Suppl. 1)):108S Solin LJ, Gray R, Baeher FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res 71(24 (Suppl. 1)):108S
Metadata
Title
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ
Authors
Laura C. Collins
Ninah Achacoso
Reina Haque
Larissa Nekhlyudov
Suzanne W. Fletcher
Charles P. Quesenberry Jr.
Stuart J. Schnitt
Laurel A. Habel
Publication date
01-06-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2539-5

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine